| Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome JE Cortes, FH Heidel, A Hellmann, W Fiedler, BD Smith, T Robak, ... Leukemia 33 (2), 379-389, 2019 | 531 | 2019 |
| Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain F Heidel, FK Solem, F Breitenbuecher, DB Lipka, S Kasper, MH Thiede, ... Blood 107 (1), 293-300, 2006 | 328 | 2006 |
| Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML FH Heidel, L Bullinger, Z Feng, Z Wang, TA Neff, L Stein, D Kalaitzidis, ... Cell stem cell 10 (4), 412-424, 2012 | 283 | 2012 |
| Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms A Prestipino, AJ Emhardt, K Aumann, D O’Sullivan, SP Gorantla, ... Science translational medicine 10 (429), eaam7729, 2018 | 232 | 2018 |
| Requirement for CDK6 in MLL-rearranged acute myeloid leukemia T Placke, K Faber, A Nonami, SL Putwain, HR Salih, FH Heidel, A Krämer, ... Blood, The Journal of the American Society of Hematology 124 (1), 13-23, 2014 | 223 | 2014 |
| Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation F Perner, C Perner, T Ernst, FH Heidel Cells 8 (8), 854, 2019 | 207 | 2019 |
| Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera A Mullally, C Bruedigam, L Poveromo, FH Heidel, A Purdon, T Vu, ... Blood, The Journal of the American Society of Hematology 121 (18), 3692-3702, 2013 | 198 | 2013 |
| Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy T Madhusudhan, H Wang, W Dong, S Ghosh, F Bock, VR Thangapandi, ... Nature communications 6 (1), 6496, 2015 | 182 | 2015 |
| Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ... Cancer 126 (6), 1243-1252, 2020 | 145 | 2020 |
| Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation S Cocciardi, A Dolnik, S Kapp-Schwoerer, FG Rücker, S Lux, TJ Blätte, ... Nature Communications 10 (1), 2031, 2019 | 131 | 2019 |
| Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms AK Jayavelu, TM Schnöder, F Perner, C Herzog, A Meiler, ... Nature 588 (7836), 157-163, 2020 | 127 | 2020 |
| JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation B Edelmann, N Gupta, TM Schnoeder, AM Oelschlegel, K Shahzad, ... The Journal of clinical investigation 128 (10), 4359-4371, 2018 | 126 | 2018 |
| Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6 IZ Uras, GJ Walter, R Scheicher, F Bellutti, M Prchal-Murphy, AS Tigan, ... Blood, The Journal of the American Society of Hematology 127 (23), 2890-2902, 2016 | 113 | 2016 |
| Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t (4; 11) ALL M Reichel, E Gillert, S AngermuÈller, JP Hensel, F Heidel, M Lode, T Leis, ... Oncogene 20 (23), 2900-2907, 2001 | 103 | 2001 |
| Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies S Kasper, F Breitenbuecher, F Heidel, S Hoffarth, B Markova, M Schuler, ... Blood cancer journal 2 (3), e60-e60, 2012 | 101 | 2012 |
| Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy C Bruedigam, FO Bagger, FH Heidel, CP Kuhn, S Guignes, A Song, ... Cell stem cell 15 (6), 775-790, 2014 | 94 | 2014 |
| Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune … F Heidel, DB Lipka, C von Auer, C Huber, I Scharrer, G Hess Thrombosis and haemostasis 97 (02), 228-233, 2007 | 86 | 2007 |
| NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells AK Jayavelu, JP Müller, R Bauer, SA Böhmer, J Lässig, S Cerny-Reiterer, ... Leukemia 30 (2), 473-483, 2016 | 82 | 2016 |
| Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway B Markova, C Albers, F Breitenbuecher, JV Melo, TH Brümmendorf, ... Oncogene 29 (5), 739-751, 2010 | 79 | 2010 |
| Novel bis (1 H-indol-2-yl) methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase S Mahboobi, A Uecker, A Sellmer, C Cénac, H Höcher, H Pongratz, ... Journal of medicinal chemistry 49 (11), 3101-3115, 2006 | 76 | 2006 |
Lars BullingerCharité University Medicine BerlinVerifisert e-postadresse på charite.de